Quality changes in commercially available etanercept (Enbrel) were found by Sandoz researchers over a period of time. Since the drug remained on the market with an unchanged label, this would indicate that the changes were accepted by the health authorities [1].
Etanercept and quality attributes changes
Biosimilars/Research | Posted 27/05/2011 0 Post your comment
The research analysed multiple commercial batches of the glycosylated recombinant therapeutic protein etanercept (Enbrel) which were available on the EU and US markets.
Glycan mapping and caution exchange chromatography were used in order to study the glycans and different acid/basic variants present in the molecule.
Results showed highly consistent quality attributes for batches expiring before the end of 2009. From 2010 onwards batches with a different quality profile appeared in parallel to the original version.
Major differences were found in the glycosylation profile and in the amount of basic variants present in the molecule. Variants containing N-glycan G2F decreased from 50% to 30% and C-terminal lysine increased from 15% to 30%.
This seems to be good news for biosimilars – which are trying to prove ‘similarity’. Since, if the originators themselves can show such variation in quality attributes, then biosimilars may find it easier to prove ‘similarity’ than may have been thought.
Related articles
Quality attributes changes for rituximab
Changes in the quality attributes of darbepoetin alfa
Acceptable changes in quality for glycosylated biologicals
Reference
1. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29(4):310-2.
News
First denosumab biosimilars approved in Canada and the US
Dr Reddy's launches bevacizumab biosimilar Versavo in the UK
General
Brazil advances in follow-on biologicals/biosimilars approvals, trailing Europe
Insurer perspective on increasing biosimilar uptake in Canada
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Comparing biosimilar adoption: Medicare Advantage versus traditional Medicare
Questioning the need for ethnic sensitivity assessments for biosimilar monoclonal antibodies
ANVISA's role in biosimilar medicine regulation and innovation promotion
Infliximab discontinuation in patients with originator retransition vs biosimilar continuation
Comments (0)
Post your comment